여성 불임 진단 시장 규모, 점유율 및 동향 분석 보고서 : 검사별, 지역별, 부문별 예측(2024-2030년)

Female Infertility Diagnosis Market Trends

The global female infertility diagnosis market size was estimated at USD 4.45 billion in 2023 and is projected to grow at a CAGR of 8.6% from 2024 to 2030. The market's growth is driven by the growing changes in lifestyle, which contribute to the rise in infertility and the prevalence of conditions such as polycystic ovary syndrome (PCOS). According to a World Health Organization (WHO) report published in June 2023, PCOS affects approximately 8-13% of women of reproductive age, with up to 70% of those affected going undiagnosed globally.

Additionally, a constant increase in the incidence of infertility in both sexes is projected to drive the market.For instance, according to a study published in Journal of Korean Medical Science, in June 2022, South Korea has experienced the most significant decline in fertility rates among all OECD countries in the last three decades. The Korean government has acknowledged the importance of promoting healthy pregnancies and childbirth considering this trend and has introduced policies aimed at addressing the low fertility rate and supporting advanced maternal age pregnancies through initiatives such as 'The Fourth Basic Plan on Low Fertility and Aging Society' launched in 2021. Consequently, the low fertility rate is expected to drive up the demand for infertility diagnosis and assisted reproductive technologies, leading to an expansion in the market growth.

The lifestyle habits play a significant role in influencing fertility in both men and women. Factors such as smoking, excessive alcohol consumption, poor diet, and sedentary habits can have detrimental effects on reproductive health. In addition, these lifestyle habits can impact fertility through various mechanisms, including hormonal imbalances, oxidative stress, inflammation, and impaired reproductive function. According to WHO, prevalence of infertility is 16.5% in low & middle income countries and 17.8% in high income countries.

Global Female Infertility Diagnosis Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the female infertility diagnosis market report based on test and region:

• Test Outlook (Revenue, USD Million, 2018 - 2030)
• Ovarian Reserve Testing
• Hysterosalpingography
• Hormone testing
• Other Tests
• Region Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Tests
    • 1.1.1.2. Regional scope
  • 1.1.2. Estimates and forecasts timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.1.3. Purchased database
  • 1.1.4. GVR's internal database
  • 1.1.5. Secondary sources
  • 1.1.6. Primary research
  • 1.1.7. Details of primary research
• 1.4. Information or Data Analysis
  • 1.1.8. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.1.9. Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Female Infertility Diagnosis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Female Infertility Diagnosis Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Female Infertility Diagnosis Market: Tests Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Female Infertility Diagnosis Market: Tests Movement Analysis
• 4.3. Female Infertility Diagnosis Market by Tests Outlook (USD Million)
• 4.4. Ovarian Reserve Testing
  • 4.4.1. Ovarian Reserve Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Hysterosalpingography
  • 4.5.1. Hysterosalpingography Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Hormone Testing
  • 4.6.1. Hormone Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Other Tests
  • 4.7.1. Other Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Female Infertility Diagnosis Market: Regional Estimates & Trend Analysis

• 5.1. Regional Dashboard
• 5.2. Regional Female Infertility Diagnosis Market: Key Takeaways
• 5.3. North America
  • 5.3.1. North America Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key Country Dynamics
    • 5.3.2.2. Competitive Scenario
    • 5.3.2.3. Regulatory Framework
    • 5.3.2.4. Reimbursement scenario
    • 5.3.2.5. U.S. Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key Country Dynamics
    • 5.3.3.2. Competitive Scenario
    • 5.3.3.3. Regulatory Framework
    • 5.3.3.4. Reimbursement scenario
    • 5.3.3.5. Canada Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key Country Dynamics
    • 5.3.4.2. Competitive Scenario
    • 5.3.4.3. Regulatory Framework
    • 5.3.4.4. Reimbursement scenario
    • 5.3.4.5. Mexico Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.5. Europe
  • 5.3.6. Europe Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.7. UK
    • 5.3.7.1. Key Country Dynamics
    • 5.3.7.2. Competitive Scenario
    • 5.3.7.3. Regulatory Framework
    • 5.3.7.4. Reimbursement scenario
    • 5.3.7.5. UK Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.8. Germany
    • 5.3.8.1. Key Country Dynamics
    • 5.3.8.2. Competitive Scenario
    • 5.3.8.3. Regulatory Framework
    • 5.3.8.4. Reimbursement scenario
    • 5.3.8.5. Germany Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.9. France
    • 5.3.9.1. Key Country Dynamics
    • 5.3.9.2. Competitive Scenario
    • 5.3.9.3. Regulatory Framework
    • 5.3.9.4. Reimbursement scenario
    • 5.3.9.5. France Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.10. Italy
    • 5.3.10.1. Key Country Dynamics
    • 5.3.10.2. Competitive Scenario
    • 5.3.10.3. Regulatory Framework
    • 5.3.10.4. Reimbursement scenario
    • 5.3.10.5. Italy Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.11. Spain
    • 5.3.11.1. Key Country Dynamics
    • 5.3.11.2. Competitive Scenario
    • 5.3.11.3. Regulatory Framework
    • 5.3.11.4. Reimbursement scenario
    • 5.3.11.5. Spain Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.12. Denmark
    • 5.3.12.1. Key Country Dynamics
    • 5.3.12.2. Competitive Scenario
    • 5.3.12.3. Regulatory Framework
    • 5.3.12.4. Reimbursement scenario
    • 5.3.12.5. Denmark Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.13. Sweden
    • 5.3.13.1. Key Country Dynamics
    • 5.3.13.2. Competitive Scenario
    • 5.3.13.3. Regulatory Framework
    • 5.3.13.4. Reimbursement scenario
    • 5.3.13.5. Sweden Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.14. Norway
    • 5.3.14.1. Key Country Dynamics
    • 5.3.14.2. Competitive Scenario
    • 5.3.14.3. Regulatory Framework
    • 5.3.14.4. Reimbursement scenario
    • 5.3.14.5. Norway Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Asia Pacific
  • 5.4.1. Asia Pacific Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Japan
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. Reimbursement scenario
    • 5.4.2.5. Japan Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. China
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Reimbursement scenario
    • 5.4.3.5. China Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. India
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. Reimbursement scenario
    • 5.4.4.5. India Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.5. South Korea
    • 5.4.5.1. Key Country Dynamics
    • 5.4.5.2. Competitive Scenario
    • 5.4.5.3. Regulatory Framework
    • 5.4.5.4. Reimbursement scenario
    • 5.4.5.5. South Korea Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.6. Australia
    • 5.4.6.1. Key Country Dynamics
    • 5.4.6.2. Competitive Scenario
    • 5.4.6.3. Regulatory Framework
    • 5.4.6.4. Reimbursement scenario
    • 5.4.6.5. Australia Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.7. Thailand
    • 5.4.7.1. Key Country Dynamics
    • 5.4.7.2. Competitive Scenario
    • 5.4.7.3. Regulatory Framework
    • 5.4.7.4. Reimbursement scenario
    • 5.4.7.5. Thailand Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Latin America
  • 5.5.1. Latin America Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Brazil
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Reimbursement scenario
    • 5.5.2.5. Brazil Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Argentina
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Reimbursement scenario
    • 5.5.3.5. Argentina Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Middle East & Africa
  • 5.6.1. Middle East & Africa Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. South Africa
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Reimbursement scenario
    • 5.6.2.5. South Africa Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. Saudi Arabia
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Reimbursement scenario
    • 5.6.3.5. Saudi Arabia Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. UAE
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Competitive Scenario
    • 5.6.4.3. Regulatory Framework
    • 5.6.4.4. Reimbursement scenario
    • 5.6.4.5. UAE Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Kuwait
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Competitive Scenario
    • 5.6.5.3. Regulatory Framework
    • 5.6.5.4. Reimbursement scenario
    • 5.6.5.5. Kuwait Female Infertility Diagnosis Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Company Market Position Analysis
• 6.3. Key Company Profiles
  • 6.3.1. PFCLA
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Service benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. Mayo Foundation for Medical Education and Research (MFMER)
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Service benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. Cleveland Clinic
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Service benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. Apricity Fertility UK Limited
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Service benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. King's Fertility Limited
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Service benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Dallas IVF
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Service benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Midwest Fertility Specialists
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Service benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. Europe IVF
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Service benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Care Fertility
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Service benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Aspire Fertility
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Service benchmarking
    • 6.3.10.4. Strategic initiatives